Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a TurnaroundZacks Investment Research • 06/14/24
Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 05/29/24
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)Benzinga • 05/21/24
RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric OpportunitySeeking Alpha • 05/20/24
Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 WeeksZacks Investment Research • 05/13/24
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsGlobeNewsWire • 04/09/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTPRNewsWire • 03/11/24
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/07/24
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/05/24
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsBusiness Wire • 02/26/24
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two TestsInvestors Business Daily • 02/20/24
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical OperationsGlobeNewsWire • 02/13/24
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewsWire • 01/31/24
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/02/24
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in AllergyGlobeNewsWire • 11/27/23
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLCGlobeNewsWire • 11/03/23